Free Trial

Checkpoint Therapeutics (CKPT) News Today

Checkpoint Therapeutics logo
$4.01 -0.03 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$3.99 -0.02 (-0.47%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from D. Boral Capital
D. Boral Capital reiterated a "buy" rating and set a $4.80 target price on shares of Checkpoint Therapeutics in a research note on Monday.
Checkpoint Therapeutics, Inc. stock logo
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Declines By 28.5%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 5,110,000 shares, a decrease of 28.5% from the February 28th total of 7,150,000 shares. Based on an average trading volume of 2,430,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 14.2% of the shares of the company are sold short.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Announces Quarterly Earnings Results
Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47).
Checkpoint Therapeutics reports FY24 EPS ($1.42) vs ($3.17) last year
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (CKPT) Projected to Post Earnings on Friday
Checkpoint Therapeutics (NASDAQ:CKPT) will be releasing earnings before the market opens on Friday, March 28, Financial Modeling Prep reports.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Given "Neutral" Rating at HC Wainwright
HC Wainwright restated a "neutral" rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Receives "Hold" Rating from Lake Street Capital
Lake Street Capital restated a "hold" rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics Target of Unusually Large Options Trading (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders purchased 5,081 call options on the stock. This represents an increase of approximately 428% compared to the average volume of 962 call options.
Checkpoint price target lowered to $4.80 from $9 at D. Boral Capital
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Given "Buy" Rating at D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a report on Monday.
Sun Pharma to Acquire Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Shares Pass Below Fifty Day Moving Average - Here's Why
Checkpoint Therapeutics (NASDAQ:CKPT) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the sale, the chief executive officer now directly owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. This trade represents a 0.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $32,542.65 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 10,331 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now owns 3,775,019 shares in the company, valued at $11,891,309.85. The trade was a 0.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Checkpoint Therapeutics, Inc. stock logo
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 74,110 Shares of Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the transaction, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Checkpoint Therapeutics, Inc. stock logo
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 8,000,000 shares, a growth of 17.5% from the December 15th total of 6,810,000 shares. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio is currently 5.7 days. Approximately 21.1% of the company's stock are sold short.
Checkpoint Therapeutics initiated with a Buy at D. Boral Capital
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics (NASDAQ:CKPT) Now Covered by D. Boral Capital
D. Boral Capital assumed coverage on Checkpoint Therapeutics in a research note on Monday. They issued a "buy" rating and a $9.00 price objective on the stock.
Checkpoint Therapeutics, Inc. stock logo
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 220,230 shares of the business's stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now owns 3,194,583 shares of the company's stock, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 268,432 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the transaction, the chief financial officer now directly owns 1,032,754 shares of the company's stock, valued at $4,141,343.54. The trade was a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in November
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 6,570,000 shares, a growth of 9.0% from the November 15th total of 6,030,000 shares. Currently, 16.2% of the shares of the company are sold short. Based on an average trading volume of 807,000 shares, the short-interest ratio is currently 8.1 days.
Checkpoint Therapeutics, Inc. stock logo
Checkpoint Therapeutics Sees Unusually High Options Volume (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders bought 7,866 call options on the company. This represents an increase of approximately 1,998% compared to the typical daily volume of 375 call options.
Checkpoint Therapeutics, Inc. stock logo
Lake Street Capital Forecasts Strong Price Appreciation for Checkpoint Therapeutics (NASDAQ:CKPT) Stock
Lake Street Capital increased their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday.
Remove Ads
Get Checkpoint Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

CKPT Media Mentions By Week

CKPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CKPT
News Sentiment

0.20

0.61

Average
Medical
News Sentiment

CKPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CKPT Articles
This Week

9

3

CKPT Articles
Average Week

Remove Ads
Get Checkpoint Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CKPT) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners